Axcan Photofrin approval
Executive Summary
Axcan Photofrin (porfimer sodium) approved by FDA Aug. 1 for ablation of high-grade dysplasia in Barrett's esophagus patients. Approval of the new indication for the photodynamic therapy follows recommendations of Gastrointestinal Drugs Advisory Committee meeting June 26 (1"The Pink Sheet" June 30, 2003, p. 18)...
You may also be interested in...
Photofrin Cancer Risk-Reduction Claim Could Follow Five-Year Study
Data from Axcan's ongoing five-year study of Barrett's esophagus patients who received Photofrin photodynamic therapy for high-grade dysplasia could lead to a future cancer risk-reduction claim, FDA's Gastrointestinal Drugs Advisory Committee suggested at its June 26 meeting
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.